Crizotinib

Crizotinib
Clinical data
Trade namesXalkori, others
Other namesPF-02341066
1066
AHFS/Drugs.comMonograph
MedlinePlusa612018
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability43%
Protein binding91%
MetabolismLiver (CYP3A4/CYP3A5-mediated)
Elimination half-life42 hours
ExcretionFaeces (63%), urine (22%)
Identifiers
  • 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.166.440 Edit this at Wikidata
Chemical and physical data
FormulaC21H22Cl2FN5O
Molar mass450.34 g·mol−1
3D model (JSmol)
  • C1(=C(C=CC(=C1[C@H](OC2=C(N=CC(=C2)C3=C[N](N=C3)C4CCNCC4)N)C)Cl)F)Cl
  • InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1 checkY
  • Key:KTEIFNKAUNYNJU-GFCCVEGCSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC).[2][3][4][5] Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms.[6] It also acts as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.[7][8][9]

Medical uses

Crizotinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) or relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.[2][3]

It is also indicated for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT).[2][10]

Mechanism of action

Human anaplastic lymphoma kinase in complex with crizotinib. PDB 2xp2[11]

Crizotinib has an aminopyridine structure, and functions as a protein kinase inhibitor by competitive binding within the ATP-binding pocket of target kinases. About 4% of patients with non-small cell lung carcinoma have a chromosomal rearrangement that generates a fusion gene between EML4 ('echinoderm microtubule-associated protein-like 4') and ALK ('anaplastic lymphoma kinase'), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype.[12] The kinase activity of the fusion protein is inhibited by crizotinib.[12] Patients with this gene fusion are typically younger non-smokers who do not have mutations in either the epidermal growth factor receptor gene (EGFR) or in the K-Ras gene.[12][13] The number of new cases of ALK-fusion NSLC is about 9,000 per year in the U.S. and about 45,000 worldwide.[14][15]

ALK mutations are thought to be important in driving the malignant phenotype in about 15% of cases of neuroblastoma, a rare form of peripheral nervous system cancer that occurs almost exclusively in very young children.[16]

Crizotinib is thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells.[6][17] Other studies suggest that crizotinib might also act via inhibition of angiogenesis in malignant tumors.[18]

Society and culture

In August 2011, the US Food and Drug Administration (FDA) approved crizotinib to treat certain late-stage (locally advanced or metastatic) non-small cell lung cancers that express the abnormal anaplastic lymphoma kinase (ALK) gene.[4] Approval required a companion molecular test for the EML4-ALK fusion. In March 2016, the FDA approved crizotinib in ROS1-positive non-small cell lung cancer.[19]

In October 2012, the European Medicines Agency (EMA) approved the use of crizotinib to treat non-small cell lung cancers that express the abnormal anaplastic lymphoma kinase (ALK) gene.[3][20]

Research

Lung cancer

Crizotinib caused tumors to shrink or stabilize in 90% of 82 patients carrying the ALK fusion gene.[13][14] Tumors shrank at least 30% in 57% of people treated.[14] [21] Most had adenocarcinoma, and had never smoked or were former smokers.[13] They had undergone treatment with an average of three other drugs prior to receiving crizotinib, and only 10% were expected to respond to standard therapy.[13][22] They were given 250 mg crizotinib twice daily for a median duration of six months.[13] Approximately 50% of these patients had at least one side effect, such as nausea, vomiting, or diarrhea.[22] Some responses to crizotinib have lasted up to 15 months.[22]

A Phase III trial, PROFILE 1007,[23] compares crizotinib to standard second line chemotherapy (pemetrexed or taxotere) in the treatment of ALK-positive NSCLC.[24][15][25] Additionally, a phase 2 trial, PROFILE 1005, studies patients meeting similar criteria who have received more than one line of prior chemotherapy.[15]

In February 2016, the J-ALEX phase III study comparing alectinib with crizotinib ALK-positive metastatic NSCLC was terminated early because an interim analysis showed that progression-free survival was longer with alectinib.[26] These results were confirmed in a 2017 analysis.[27]

Lymphomas

In people affected by relapsed or refractory ALK+ anaplastic large cell lymphoma, crizotinib produced objective response rates ranging from 65% to 90% and 3 year progression free survival rates of 60–75%. No relapse of the lymphoma was ever observed after the initial 100 days of treatment. Treatment must be continued indefinitely at present.[28][29][30]

Other cancers

Crizotinib is also being tested in clinical trials of advanced disseminated neuroblastoma.[31]

References

  1. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  2. ^ a b c d "Xalkori- crizotinib capsule". DailyMed. Archived from the original on 9 October 2021. Retrieved 18 April 2021.
  3. ^ a b c d "Xalkori EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 19 April 2021. Retrieved 18 April 2021.
  4. ^ a b "Drug Approval Package: Xalkori Capsules (crizotinib) NDA #202570". U.S. Food and Drug Administration (FDA). 27 September 2011. Archived from the original on 7 April 2021. Retrieved 18 April 2021.
  5. ^ "Summary Review for Regulatory Action" (PDF). U.S. Food and Drug Administration (FDA). 26 August 2011. Archived (PDF) from the original on 6 April 2021. Retrieved 19 April 2021.
  6. ^ a b Clinical trial number NCT00585195 for "A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer" at ClinicalTrials.gov
  7. ^ Forde PM, Rudin CM (June 2012). "Crizotinib in the treatment of non-small-cell lung cancer". Expert Opinion on Pharmacotherapy. 13 (8): 1195–201. doi:10.1517/14656566.2012.688029. PMID 22594847. S2CID 23715951.
  8. ^ Roberts PJ (2013). "Clinical use of crizotinib for the treatment of non-small cell lung cancer". Biologics: Targets and Therapy. 7: 91–101. doi:10.2147/BTT.S29026. PMC 3643289. PMID 23671386.
  9. ^ Sahu A, Prabhash K, Noronha V, Joshi A, Desai S (April 2013). "Crizotinib: A comprehensive review". South Asian Journal of Cancer. 2 (2): 91–7. doi:10.4103/2278-330X.110506 (inactive 1 November 2024). PMC 3876666. PMID 24455567.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
  10. ^ "FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor". U.S. Food and Drug Administration (FDA) (Press release). 14 July 2022. Archived from the original on 14 July 2022. Retrieved 14 July 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  11. ^ Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, et al. (September 2011). "Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)". Journal of Medicinal Chemistry. 54 (18): 6342–63. doi:10.1021/jm2007613. PMID 21812414.
  12. ^ a b c "Maintenance Therapy for Non-Small Cell Lung Cancer". MedscapeCME. 12 May 2010. Archived from the original on 6 December 2012. Retrieved 7 June 2010.
  13. ^ a b c d e "ALK inhibitor crizotinib has high response rate in patients with ALK-positive NSCLC". HemOncToday. 5 June 2010. Archived from the original on 6 April 2020. Retrieved 7 June 2010.
  14. ^ a b c Winslow R (7 June 2010). "Advances Come in War on Cancer". The Wall Street Journal. Archived from the original on 9 October 2021. Retrieved 7 June 2010.
  15. ^ a b c "Pfizer Oncology To Present New Clinical Data From Ten Molecules Across Multiple Tumor Types" (PDF) (Press release). Pfizer Oncology. 20 May 2010. Archived from the original (PDF) on 12 June 2010. Retrieved 7 June 2010.
  16. ^ Janoueix-Lerosey I, Schleiermacher G, Delattre O (March 2010). "Molecular pathogenesis of peripheral neuroblastic tumors". Oncogene. 29 (11): 1566–79. doi:10.1038/onc.2009.518. PMID 20101209.
  17. ^ Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. (December 2007). "Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma". Molecular Cancer Therapeutics. 6 (12 Pt 1): 3314–22. doi:10.1158/1535-7163.MCT-07-0365. PMID 18089725.
  18. ^ Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. (May 2007). "An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms". Cancer Research. 67 (9): 4408–17. doi:10.1158/0008-5472.CAN-06-4443. PMID 17483355.
  19. ^ "NICE backs Pfizer's Xalkori after squeezing out a new discount – FiercePharma". 18 August 2016. Archived from the original on 8 August 2020. Retrieved 18 August 2016.
  20. ^ "Xalkori - EMEA/H/C/002489 - T/0059" (PDF). European Medicines Agency. 2012. Archived (PDF) from the original on 4 October 2018. Retrieved 22 October 2018.
  21. ^ Helwick (2010). "Novel Agent Demonstrates Striking Activity in ALK-positive NSCLC". Archived from the original on 28 January 2011. NB Fig 1.
  22. ^ a b c "Gene-based lung cancer drug shows promise". NBC News. 7 May 2010. Retrieved 7 June 2010.[dead link‍]
  23. ^ "Crizotinib Clinical Trials – Currently Ongoing and/or Enrolling" (PDF). Fact Sheet. Pfizer. Archived (PDF) from the original on 3 March 2016. Retrieved 16 August 2014.
  24. ^ Clinical trial number NCT00932451 for "An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene" at ClinicalTrials.gov
  25. ^ Clinical trial number NCT00932893 for "An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene" at ClinicalTrials.gov
  26. ^ "Chugai's ALK Inhibitor "Alecensa" Trial Stopped Early for Benefit" (PDF). Roche. February 2016. Archived (PDF) from the original on 18 April 2016. Retrieved 8 December 2017.
  27. ^ "FDA approves Alecensa for ALK-positive metastatic non-small cell lung cancer". Healio. November 2017. Archived from the original on 9 December 2017. Retrieved 8 December 2017.
  28. ^ Gambacorti-Passerini C, et al. (2010). "Clinical Activity of Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients". Annual Meeting of the American Society of Hematology. Orlando, Florida.
  29. ^ Gambacorti-Passerini C, Messa C, Pogliani EM (February 2011). "Crizotinib in anaplastic large-cell lymphoma". The New England Journal of Medicine. 364 (8): 775–6. doi:10.1056/NEJMc1013224. PMID 21345110.
  30. ^ Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, et al. (February 2014). "Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients". Journal of the National Cancer Institute. 106 (2): djt378. doi:10.1093/jnci/djt378. PMID 24491302.
  31. ^ Wood AC, Laudenslager M, Haglund EA, Attiyeh EF, Pawel B, Courtright J, Plegaria J, Christensen JG, Maris JM, Mosse YP (2009). "Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066". J Clin Oncol. 27 (15s. suppl, abstr 10008b): 10008b. doi:10.1200/jco.2009.27.15_suppl.10008b. Archived from the original on 16 August 2014.
  • "Crizotinib". NCI Drug Dictionary. National Cancer Institute.
  • "Crizotinib". National Cancer Institute. 11 October 2011.
  • Clinical trial number NCT00585195 for "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)" at ClinicalTrials.gov
  • Clinical trial number NCT00932893 for "An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene" at ClinicalTrials.gov
  • Clinical trial number NCT00939770 for "Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma" at ClinicalTrials.gov
  • Clinical trial number NCT01154140 for "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)" at ClinicalTrials.gov
  • Clinical trial number NCT01979536 for "Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma" at ClinicalTrials.gov

Read other articles:

Playboy Indonesia

Playboy IndonesiaPlayboy Indonesia edisi perdana dengan model sampul Andhara Early.Mantan Pemimpin RedaksiErwin ArnadaKategoriMajalah pria dewasaFrekuensiBulananPenerbitPT Velvet Silver MediaPendiriErwin ArnadaTerbitan pertamaApril 2006Terbitan terakhirAngkaMaret 200711Negara IndonesiaBerpusat diJakartaBali (sejak edisi ke-2)BahasaIndonesia Playboy Indonesia adalah edisi majalah Playboy dalam bahasa Indonesia. Edisi perdananya terbit pada bulan 7 April 2006 dan ditutup pada Maret 2007. &...

 

Aimé De Gendt

Cet article est une ébauche concernant un coureur cycliste belge. Vous pouvez partager vos connaissances en l’améliorant (comment ?). Pour plus d’informations, voyez le projet cyclisme. Aimé De GendtAimé De Gendt lors du Grand Prix de Denain 2016.InformationsNaissance 17 juin 1994 (29 ans)AlostNationalité belgeÉquipe actuelle CofidisÉquipes non-UCI 2011Avia2012Avia Fuji Youth2013-2014EFC-Omega Pharma-Quick Step2015EFC-EtixxÉquipes UCI 2016Topsport Vlaanderen-Baloise2017...

 

Chiune Sugihara

Chiune SugiharaFoto Chiune SugiharaLahir1 Januari 1900Mino, Gifu, JepangMeninggal31 Juli 1986Fujisawa, JepangPekerjaanDiplomat Chiune Sugihara (杉原千畝code: ja is deprecated , Sugihara Chiune, 1 Januari 1900 – 31 Juli 1986) adalah seorang diplomat Jepang yang menyelamatkan ribuan orang Yahudi pada masa Perang Dunia II ketika ia menjabat sebagai konsul Kekaisaran Jepang di Lituania. Ia adalah salah seorang yang tampaknya tidak mempunyai motivasi lain kecuali melakukan apa...

Ampulla

For anatomy and other uses, see Ampulla (disambiguation). Eulogy ampulla representing St. Menas and St. Thecla (terracotta, 6th century, Louvre Museum) An ampulla (/æmˈpʊlə, -ˈpʌl-/;[1] pl.: ampullae) was, in Ancient Rome, a small round vessel, usually made of glass and with two handles, used for sacred purposes. The word is used of these in archaeology, and of later flasks, often handle-less and much flatter, for holy water or holy oil in the Middle Ages, often bought as souven...

 

NGC 4444

Galaxy in the constellation Centaurus NGC 4444DSS image of NGC 4444Observation data (J2000 epoch)ConstellationCentaurusRight ascension12h 28m 36.419s[1]Declination−43° 15′ 42.15″[1]Redshift0.009771[1]Heliocentric radial velocity2915 km/s[1]Distance(38.8 ± 5.7 Mpc)[2]CharacteristicsTypeSAB(rs)bc[3]Mass5.8 × 109[4] M☉Apparent size (V)2′.4 × 1′.6[5]Other designationsMCG -07-26-007...

 

Stadio Città di Arezzo

Città di Arezzo Informazioni generaliStato Italia UbicazioneVia Antonio Gramsci52100 Arezzo (AR) Inizio lavori1959 Inaugurazione1961 Ristrutturazione1992, 2004 ProprietarioArezzo GestoreSocietà Sportiva Arezzo Informazioni tecnichePosti a sedere13.128[1] - omologati 7.450 CoperturaTribuna Pista d’atleticapresente Mat. del terrenoerba Dim. del terreno105 × 68 m Uso e beneficiariCalcio Arezzo Mappa di localizzazione Modifica dati su Wikidata · ManualeCoordinate: 43�...

Список вооружения и военной техники Исламского государства

Эту страницу предлагается переименовать в «Список вооружения и военной техники «Исламского государства»».Пояснение причин и обсуждение — на странице Википедия:К переименованию/27 марта 2017. Пожалуйста, основывайте свои аргументы на правилах именования статей. Не уда�...

 

هايسفيل

  لمعانٍ أخرى، طالع هايسفيل (توضيح). هايسفيل   الإحداثيات 41°15′52″N 92°14′56″W / 41.2644°N 92.2489°W / 41.2644; -92.2489   [1] تقسيم إداري  البلد الولايات المتحدة[2]  التقسيم الأعلى مقاطعة كيوكوك  خصائص جغرافية  المساحة 0.654666 كيلومتر مربع (1 أبريل 2010)  ارت�...

 

Naval Facilities Engineering Systems Command

One of the systems commands of the United States Navy Not to be confused with SOSUS Shore facilities, which are also called Naval Facility (NAVFAC). 38°52′26.1″N 76°59′44.1″W / 38.873917°N 76.995583°W / 38.873917; -76.995583 Naval Facilities Engineering Systems Command(NAVFAC)Founded1966; 58 years ago (1966)Allegiance United States of AmericaBranch United States NavyTypeSYSCOMGarrison/HQWashington Navy Yard, Washington D.C., U.S....

Ndrek Luca

Ndrek Luca Född3 september 1927Dukagjin, AlbanienDöd13 januari 1993 (65 år)Tirana, AlbanienMedborgare iAlbanienSysselsättningSkådespelareRedigera Wikidata Ndrek Luca, född den 3 september 1927 i Shkodra i Albanien, död den 13 januari 1993 i Tirana i Albanien, var en albansk skådespelare som medverkat i 30 filmer. Källor Elsie, Robert (2013) (på engelska). A Biographical Dictionary of Albanian History. London: I.B. Tauris, in Association with the Centre for...

 

داخنة

داخنةمعلومات عامةصنف فرعي من volcanic phenomenon (en) شكل الأرض تعديل - تعديل مصدري - تعديل ويكي بياناتدخان الفومارول من إحدى براكين ألاسكا في 2006 صورة من طائرة لفوهة هاليماوماو (هاواي) عام 2009. الداخنة[1] (أو النافثة البركانية)[2] هو دخان يخرج من فوق القشرة الأرضية وعادةً ما يخرج ق...

 

الدوري العراقي الممتاز 1982–83

الدوري العراقي الممتاز السلسلة دوري نجوم العراق  الموسم 1982–83 البلد العراق  الفرق 12   الفائز صلاح الدين(اللقب الأول) هداف الدوري حسين سعيد(17 هدف) 1981–82 1983–84 تعديل مصدري - تعديل   دوري أندية العراق للدرجة الأولى 1982–83 هي الموسم التاسع من الدوري العراقي الممتاز منذ ت�...

Battle of the Brave

2004 film Battle of the BraveQuebec release posterNouvelle-FranceDirected byJean BeaudinWritten byPierre BillonProduced byRichard Goudreau Robert SidawayStarringNoémie Godin-VigneauDavid La HayeJuliette GosselinSébastien HuberdeauGérard DepardieuCinematographyLouis de ErnstedEdited byJean-François BergeronYves LangloisMusic byPatrick DoyleDistributed byMetropolitan Filmexport (France)[1]Release date 19 November 2004 (2004-11-19) Running time143 minutesCountriesCanad...

 

Ali al-Hadi

Tenth of the Twelve Shia Imams (828–868) Ali al-HadiTenth Imam of Twelver Shi'ismعَلِيّ ٱلْهَادِيCalligraphic inscription of al-Hadi's name on the zarih of Husayn ibn Ali, located in Karbala10th Shia ImamIn office835–868Preceded byMuhammad al-JawadSucceeded byHasan al-Askari Title al-Hadi (lit. 'the guide') al-Naqi (lit. 'the distinguished') PersonalBornc. 7 March 828 CE (16 Dhu al-Hijja 212 AH)Medina, Abbasid EmpireDiedc. 21 June 868(868-06-21) (age...

 

Four Corners

Only region in the United States where four states share a boundary point This article is about the region in the southwestern United States. For the monument, see Four Corners Monument. For other uses, see Four Corners (disambiguation). The Four Corners region is the red circle in this map. The Four Corners states are highlighted in orange. False-color satellite image of the Four Corners. Bright red lines are vegetation along the major rivers of the area. A young Navajo boy on horseback in M...

The Songs of Bilitis

Collection of French erotic lesbian poetry in the manner of Sappho by Pierre Louÿs, 1894. The Songs of Bilitis Illustration by Georges Barbier for The Songs of BilitisAuthorPierre LouÿsOriginal titleLes Chansons de BilitisLanguageFrenchGenrePoetry, eroticaPublication date1894Publication placeFranceMedia typePrint The Songs of Bilitis (/bɪˈliːtɪs/; French: Les Chansons de Bilitis) is a collection of erotic, essentially lesbian, poetry by Pierre Louÿs published in Paris in 1894...

 

Corona all'antica

Corona all'antica d'oro, di sette punte visibili In araldica è detta corona all'antica (ma anche corona antica o corona radiata) il cerchio d'oro sormontato da 12 punte aguzze a rappresentare i mesi dell'anno[1], di cui solo 7 visibili. In qualche caso le punte visibili sono solo 5 o 3. Una corona di questo tipo compare in medaglie di Caligola, Traiano o Marco Aurelio come simbolo di divinità poiché pare formata da raggi.[1] La corona all'antica compare spesso come decorazi...

 

Snoop Dogg

Snoop Dogg Snoop Dogg en 2019Información personalNombre de nacimiento Calvin Cordozar Broadus Jr.Nacimiento 20 de octubre de 1971 (52 años)Long Beach, California, Estados UnidosNacionalidad EstadounidenseReligión CristianismoLengua materna Inglés Características físicasAltura 1,93 m FamiliaCónyuge Shante Taylor (matr. 1997; div. 2004)Shante Taylor (matr. 2008)Hijos 4EducaciónEducado en Compton College Información profesionalOcupación Rapero[1...

Elias M. Stein

American mathematicianBản mẫu:SHORTDESC:American mathematicianElias M. SteinStein năm 2008Sinh(1931-01-13)13 tháng 1, 1931Antwerp, BỉMất23 tháng 12, 2018(2018-12-23) (87 tuổi)Somerville, New Jersey, Hoa KỳQuốc tịchHoa KỳTrường lớpUniversity of Chicago (Ph.D., 1955)Nổi tiếng vìStein–Strömberg theorem Princeton Lectures on Analysis textbook seriesPhối ngẫuElly IntratorCon cáiKaren Stein Jeremy C. SteinGiải thưởngRolf Schock Prize in Mathemat...

 

Shell (computing)

Computer program that exposes an operating system's services to a human user or other programs A graphical interface similar to one from the late 1980s, which features a TUI window for a man page, a shaped window (oclock) as well as several iconified windows. In the lower right we can see a terminal emulator running a Unix shell, in which the user can type commands as if they were sitting at a terminal. In computing, a shell is a computer program that exposes an operating system's services to...